Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yi'nao Jieyu Granules (YNJYD) is a traditional Chinese medicine (TCM) herbal formulation primarily used for the treatment of depression and post-stroke depression. The granule form is standardized according to the guidelines in the 2010 edition of the Chinese Pharmacopeia. Its main ingredients are Acanthopanax senticosus (20 g) and Schisandra chinensis (10 g), both well-known TCM herbs with neuroprotective and adaptogenic properties. Preclinical studies indicate that YNJYD exerts therapeutic effects by improving microcirculation in brain regions such as the prefrontal cortex and hippocampus, regulating glutamatergic neurotransmission, modulating membrane phospholipid metabolism, repairing microstructural damage, and alleviating depressive-like behaviors in animal models. The mechanism appears to involve modulation of neurotransmitter systems including gamma-aminobutyric acid type A receptor activity[1][2][9]. Clinical development includes evaluation for efficacy and safety in patients with kidney deficiency-liver stagnation type depression[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yi'nao Jieyu Granules.